Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ssCART-19 vs CD19 CAR-T in R/R ALL
NCT03275493Phase 2Recruiting
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.
- Start
- Jul 2017
- Primary completion
- Dec 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ssCART-19 in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd. Primary endpoint: Incidence of severe Cytokine Release Syndrome (CRS) at 30 days. Started Jul 2017; status: recruiting.
02
Drugs
ssCART-19
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03275493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275493.